The role of cardiovascular pharmacology and therapeutics extends far beyond traditional drug regimens, encompassing groundbreaking treatments that address the intricate mechanisms of heart diseases. Recent developments include RNA-based therapies and regenerative drugs designed to repair cardiac tissue at a molecular level. Researchers are also investigating the role of anti-inflammatory agents in reducing atherosclerosis progression. Clinical trials for novel anticoagulants and lipid-lowering medications continue to refine strategies for preventing thrombotic events and improving long-term patient health. This dynamic field integrates pharmacological advances with patient-specific approaches to enhance both the efficacy and safety of cardiovascular care.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title :
Federico Benetti, Benetti Foundation, Argentina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation